31-Dec-2025
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Globe Newswire (Wed, 17-Dec 7:00 AM ET)
Market Chameleon (Wed, 10-Dec 6:45 AM ET)
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Globe Newswire (Tue, 9-Dec 6:35 PM ET)
Globe Newswire (Fri, 5-Dec 7:00 AM ET)
Globe Newswire (Mon, 1-Dec 4:10 PM ET)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 1-Dec 4:05 PM ET)
Biomea Fusion to Participate at Upcoming Investor Conferences
Globe Newswire (Mon, 24-Nov 7:00 AM ET)
Biomea Fusion to Participate at Jefferies London Healthcare Conference
Globe Newswire (Mon, 10-Nov 7:00 AM ET)
Globe Newswire (Wed, 5-Nov 7:00 AM ET)
Biomea Fusion Reports Third Quarter 2025 Financial Results and Corporate Highlights
Globe Newswire (Tue, 4-Nov 4:05 PM ET)
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
Biomea Fusion trades on the NASDAQ stock market under the symbol BMEA.
As of December 31, 2025, BMEA stock price climbed to $1.24 with 829,726 million shares trading.
BMEA has a beta of 1.50, meaning it tends to be more sensitive to market movements. BMEA has a correlation of 0.07 to the broad based SPY ETF.
BMEA has a market cap of $87.67 million. This is considered a Micro Cap stock.
In the last 3 years, BMEA traded as high as $43.69 and as low as $.87.
The top ETF exchange traded funds that BMEA belongs to (by Net Assets): VTI, VXF, IWC, MSSM.
BMEA has underperformed the market in the last year with a price return of -68.0% while the SPY ETF gained +17.2%. BMEA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -38.6% and -9.5%, respectively, while the SPY returned +2.7% and +0.7%, respectively.
BMEA support price is $1.13 and resistance is $1.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMEA shares will trade within this expected range on the day.
